Home Sectors Healthcare Current Valuation: United Therapeutics Corporation (NASDAQ: UTHR)

Current Valuation: United Therapeutics Corporation (NASDAQ: UTHR)


United Therapeutics Corporation is part of the biotechnology industry and is part of the healthcare sector. The company CEO is Martine A. Rothblatt. United Therapeutics Corp is engaged in the healthcare sector. Its core offering includes pharmaceutical products to address unmet medical needs of patients.

Previous Intraday Trading Performance:

The UTHR stock showed a previous change of 1.08% with an open at 124.83 and a close of 126.17. It reached an intraday high of 128.88 and a low of 123.23.

SeekingAlpha:  United Therapeutics Releases Positive Data On PAH Drug - What Investors Should Know.


The stock has a market cap of $5.5b with 43.6m shares outstanding, of which the float is 43.5m shares. Trading volume reached 1,018,328 shares compared to its average volume of 356,080 shares. Based on the current average volume and close price, the trading liquidity is good.

Historical Trading Performance:

Over the last five trading days, United Therapeutics Corporation shares returned 2.38% and in the past 30 trading days it returned 16.33%. Over three months, it changed 23.21%. In one year it has changed -6.86% and within that year its 52-week high was 152.55 and its 52-week low was 100.57. UTHR stock is 25.45% above its 52 Week Low.

Our calculations show a 200 day moving average of 121.40 and a 50 day moving average of 117.72. Currently UTHR stock is trading 3.93% above its 200 day moving average and may be a good opportunity to buy.

PR Newswire:  United Therapeutics Announces Settlement Of Patent Litigation With Watson Laboratories, Inc. Relating To Tyvaso


The last annual fiscal EPS for the company was reported at 9.39 that ended on 31st of December 2017, which according to the previous close, that is a PE of 13.44. Based on 2 analyst estimates, the consensus EPS for the next quarter is 2.57. The TTM EPS is 17.88, which comes to a TTM PE of 7.06. Historically, the PE high was 42.30 and the PE low was 7.06. UTHR stock has set a new PE low record!

The following are the last four quarter reported earnings per share:
06-30-2018:  3.98
03-31-2018:  5.57
12-31-2017:  2.06
09-30-2017:  6.27

Base on our calculations, the intrinsic value per share is 239.09, which means it is possibly undervalued and has a margin of safety of 47.23%

Indicators to Watch:

Based on the latest filings, there is 98.40% of institutional ownership. Short-interest is 3,356,500, which is 7.70% of shares outstanding. The short-interest ratio or days-to-cover ratio is 10.87. This stock has a moderate level of short interest, but may still be a buying opportunity depending on other indicators.

The current calculated beta is 1.26

PR Newswire:  United Therapeutics Announces Settlement Of Patent Litigation With Watson Laboratories, Inc. Relating To Tyvaso

Fundamental Indicators:

Based on last reported financials, the company's return on equity is 32.24%, return on assets is 23.77%, profit margin is 40.34%, price-to-sales is 3.12 and price-to-book is 2.10.

Company Scores:

All scores are out of six:
 5  :Valuation Score
 6  :Past Performance Score
 6  :Financial Strength Score
 0  :Future Growth Score
 0  :Dividend Score
 4  :Overall Score

John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks. Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.


Please enter your comment!
Please enter your name here